- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- You can view the full Johnson & Johnson Ratings Report.
Doug Kass shares his thoughts on Treasury notes and bonds, and offers some other observations.
South Korea's Samsung Bioepis is looking to sell its version of the drug in the U.S.